The heart of gene therapy: BioCardia sets terms for $50 million IPO

BioCardia, which is developing gene therapies for cardiovascular diseases, announced terms for its IPO on Monday.

The San Carlos, CA-based company plans to raise $50 million by offering 3.85 million shares at a price range of $12 to $14. At the midpoint of the proposed range, BioCardia would command a fully diluted market value of $154 million.

BioCardia, which was founded in 2002, plans to list on the NASDAQ under the symbol BCDA. Cantor Fitzgerald, Roth Capital and Maxim Group LLC are the joint bookrunners on the deal.